SOHO 2021 | The pharmacokinetics of pirtobrutinib
Catherine C. Coombs, MD, The University of North Carolina Cancer Center, Chapel Hill, NC, discusses the pharmacokinetics of the highly-selective non-covalent Bruton’s tyrosine kinase inhibitor (BTKi), pirtobrutinib, and explains how the mechanism of action of this next-generation BTKi can offer superior outcomes and quality of life. Pirtobrutinib has a 300-fold greater selectivity for BTK compared to other kinases on the kinome selectivity map, indicating fewer off-target effects and thus having a more favorable safety profile. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
Disclosures
Catherine C. Coombs, MD, has received honoraria or participated in consultancy work for AbbVie, Genentech, AstraZeneca, LOXO, Novartis and MEI Pharma; and has received institutional funding from AbbVie, LOXO, Incyte and h3 biomedicine.
